BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Other Events
Item 8.01 Other Events.
On January25, 2017, BeiGene,Ltd. (the Company) issued a press
release announcing the initiation of a global Phase III clinical
trial of its investigational Brutons Tyrosine Kinase (BTK)
inhibitor, BGB-3111, in patients with Waldenstrms
macroglobulinemia (WM).The study is designed to determine whether
the quality of response with BGB-3111 in WM is superior to that
of ibrutinib, an approved BTK inhibitor. The full text of the
Companys press release is filed as Exhibit99.1 to this Current
Report on Form8-K and is incorporated herein by reference.
Item9.01 Financial Statements and
Exhibits.
(d) Exhibits.
|
ExhibitNo. |
|
Description |
|
99.1 |
Press Release issued on January25, 2017 |
About BEIGENE, LTD. (NASDAQ:BGNE)
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers. BEIGENE, LTD. (NASDAQ:BGNE) Recent Trading Information
BEIGENE, LTD. (NASDAQ:BGNE) closed its last trading session up +2.26 at 35.26 with 74,560 shares trading hands.
